CHARLESTON — West Virginia Attorney General Patrick Morrisey reached a multistate settlement to resolve allegations that a pharmaceutical company falsely and aggressively marketed and promoted Suboxone, leading to improper use of state Medicaid funds.
The company, Indivior, will provide West Virginia more than $5.2 million. The state will keep more than $1.36 million, while the balance will reimburse federal Medicaid programs – a matter consistent with previous Medicaid settlements.
“Marketing a product using false claims — particularly claims regarding safety of a drug — can have dangerous outcomes,” Attorney General Morrisey said. “This type of fraud also takes Medicaid resources away from those who need them most. We must never cease in our efforts to root out fraud, waste and abuse.”
The settlement resolves allegations that from 2010 to 2015 Indivior promoted the sale and use of Suboxone to physicians that prescribed the drug without legitimate medical purpose and knowingly promoted the sale or use of Suboxone film based on false or misleading claims that it was less susceptible to diversion than Suboxone tablets.
The agreement also resolves allegations that Indivior submitted a petition to federal regulators in September 2012 fraudulently claiming the Suboxone tablet had been discontinued in an attempt to delay generic competitors entering the market.
Nationally, more than two-thirds of Indivior’s $300 million payout will go to the Medicaid programs.
The West Virginia Bureau of Medicaid Services will receive approximately $583,384 of the state’s share.
This is West Virginia’s second settlement to resolve Medicaid fraud allegations related to the sale and marketing of Suboxone. The first, announced in late 2019, was valued at $700 million nationally and resolved allegations against the maker of Suboxone, Reckitt Benckiser Group.
Indivior Inc., formerly a part of Reckitt Benckiser Group, split from Reckitt Benckiser prior to the 2019 settlement.